HC Wainwright & Co. maintains Buy rating on Compass Therapeutics, $12 price target

HC Wainwright & Co. maintained their Buy rating on Compass Therapeutics's stock with a price target of $12.00.The price target implies an upside of 867.7% from the Sep 22 close of $1.24.Key takeaways from the analyst noteStrong Pipeline of Innovative Therapies: Compass Therapeutics has developed a…